Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | $73.6M | $115.9M | $159.6M | $210.9M | $281.5M | $369.8M | $603.8M | $743.2M | $916.1M | $1,117.0M | $1,288.5M | $1,465.8M | $1,598.8M | $1,725.3M | $1,627.8M | $1,448.8M | $1,483.3M | $1,685.5M | $1,936.3M | $2,327.5M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Revenue is $2,756.2M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Revenue growth was 25.0%. The average annual Revenue growth rates for United Therapeutics Corporation have been 22.3% over the past three years, 12.7% over the past five years.
Over the last year, United Therapeutics Corporation's Revenue growth was 25.0%, which is higher than industry growth of 3.1%. It indicates that United Therapeutics Corporation's Revenue growth is Good.